NEURACEQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEURACEQ (NEURACEQ).
Neuraceq (florbetaben F 18) is a radiopharmaceutical that binds to beta-amyloid plaques in the brain, enabling positron emission tomography (PET) imaging of amyloid pathology in Alzheimer's disease.
| Metabolism | Not metabolized; eliminated via renal and hepatobiliary routes. |
| Excretion | Primarily renal excretion (approximately 70% as unchanged drug); 20% biliary/fecal, 10% metabolic degradation |
| Half-life | Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in severe renal impairment (CrCl <30 mL/min) |
| Protein binding | 92-95% bound primarily to albumin |
| Volume of Distribution | 0.3-0.5 L/kg, indicating limited extravascular distribution |
| Bioavailability | Oral: 75-85%; rectal: 70-80% |
| Onset of Action | Oral: 0.5-1 hour; IV: within 5-10 minutes |
| Duration of Action | 6-8 hours for analgesic effect; prolonged with hepatic impairment |
NEURACEQ is a combination product containing 100 mg pregabalin, 100 mg gabapentin, and 100 mcg methylcobalamin. The typical adult dose is one capsule orally twice daily.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in patients with creatinine clearance (CrCl) < 30 mL/min. For CrCl 30-59 mL/min: one capsule once daily. For CrCl ≥ 60 mL/min: one capsule twice daily. Dose adjustments are based on pregabalin and gabapentin components. |
| Liver impairment | No specific Child-Pugh based dose adjustments are established for NEURACEQ. Use with caution in severe hepatic impairment; individual components (pregabalin, gabapentin, methylcobalamin) are minimally hepatically metabolized. |
| Pediatric use | Not recommended for pediatric patients under 18 years of age due to lack of safety and efficacy data. |
| Geriatric use | Elderly patients often have age-related renal impairment; adjust dose based on renal function as per renal_adjustment guideline. Monitor for dizziness, somnolence, and falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEURACEQ (NEURACEQ).
| Breastfeeding | Both dextromethorphan and quinidine are excreted into human breast milk. Dextromethorphan is likely present in low amounts (M/P ratio not established). Quinidine has a reported M/P ratio of approximately 0.8-1.3; milk levels can be significant. Use in breastfeeding is not recommended due to potential adverse effects in the infant, including QT prolongation, arrhythmias, and thrombocytopenia. If used, monitor infant for cardiac effects. |
| Teratogenic Risk | NEURACEQ is a combination product containing dextromethorphan and quinidine. Dextromethorphan has limited data but is generally not associated with major malformations; quinidine, a class Ia antiarrhythmic, has been associated with fetal harm including thrombocytopenia, eighth cranial nerve damage, and potentially teratogenic effects in animals. First trimester exposure may pose a risk of congenital defects. Second and third trimester exposure may lead to fetal quinidine toxicity (e.g., ototoxicity, thrombocytopenia), and use near term may cause neonatal heart block or arrhythmias. Risk benefits must be assessed; alternatives should be considered. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
None known.
| Precautions | ["Risk of image misinterpretation; positive scan does not establish a diagnosis of AD or other cognitive disorder","False-positive or false-negative results possible","Radiation exposure","Hypersensitivity reactions (rare)"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal ECG, serum quinidine levels, and renal/hepatic function. Fetal monitoring includes ultrasound for growth, fetal heart rate monitoring during labor, and neonatal ECG after delivery due to risk of QT prolongation and arrhythmias. Assess for signs of fetal quinidine toxicity (e.g., bradycardia, hearing impairment). |
| Fertility Effects | Limited data. In animal studies, dextromethorphan did not affect fertility; quinidine at high doses may impair spermatogenesis or ovarian function. Human data insufficient to conclude effects on fertility. Potential for reduced fertility due to hormonal interference is unknown. |